mailitics

Category: Biotech

  • Pfizer discontinues its experimental GLP-1 pill

    Pfizer discontinues its experimental GLP-1 pill Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss interesting new gene-editing data from Verve, see the NIH starting to convene advisory councils again, and more. Read the rest… Meghana Keshavan Go to statnews

  • NIH hit with chaos, cuts, and contractor purge

    NIH hit with chaos, cuts, and contractor purge Hello. Today, we dive into the implications of the ongoing cuts to various health and science agencies….It’s a doozy. Oh, and if you like talking about neuroscience and happen to be near San Diego this weekend, come hang with me and my colleagues at STAT@AAN: The Future…

  • STAT+: FDA Commissioner Marty Makary gets off to a bruising start as agency is wracked by layoffs

    STAT+: FDA Commissioner Marty Makary gets off to a bruising start as agency is wracked by layoffs WASHINGTON — Marty Makary’s first official day as commissioner of the Food and Drug Administration began with employees in tears, learning from security guards that they were losing their jobs. The news release announcing the start of his…

  • Emotional whiplash for PTC Therapeutics

    Emotional whiplash for PTC Therapeutics Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we process the shockwaves in biotech following the ouster of CBER chief Peter Marks, see a radiopharmaceutical expand its reach, and more. Read the rest… Meghana Keshavan…

  • Opinion: STAT+: Peter Marks’ ouster is an ominous sign for biotech — and for public health

    Opinion: STAT+: Peter Marks’ ouster is an ominous sign for biotech — and for public health Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. There are certain leaders who quietly make complex organizations operate well including in the toughest of times — leaders like Peter Marks, director of…

  • STAT+: FDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences

    STAT+: FDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the agency’s leadership ranks and threatens to unmoor the oversight of drugs and vaccines from bedrock scientific principles.  For biotech…

  • STAT+: Ouster of FDA’s Peter Marks alarms a biopharma industry that saw him as an ally

    STAT+: Ouster of FDA’s Peter Marks alarms a biopharma industry that saw him as an ally When Robert F. Kennedy Jr., a longtime and visceral critic of pharmaceutical and biotech companies, was nominated by President Trump to be the nation’s health secretary, the head of biotech’s largest trade group issued a statement saying that he…

  • Peter Marks, FDA’s top vaccine regulator, forced out

    Peter Marks, FDA’s top vaccine regulator, forced out Peter Marks, the top Food and Drug Administration official who oversaw vaccines, gene therapies, and the blood supply, resigned Friday after being told by Trump administration officials he would be fired if he did not step down, according to people familiar with the situation. In his resignation…